DIA Workshop on Benefit-Risk Strategy Prague, Czech Republic 15-16 June 2017

Description:
Are you aware of the key developments on the benefit-risk guidelines?

Benefit-risk guidelines continue to evolve with the EMA publishing guidance revisions as recently as this March. This workshop provides you the tools to address these changes by giving you:

- Overview of benefit-risk assessments
- Examples of challenges and solutions across different departments
- Impacts and interpretations of the new guidelines

EMA experts join this workshop to give you tangible insights and tips to navigate the evolving benefit-risk guidelines. The hands-on workshop structure provides you with real-world examples from regulatory and industry perspectives, and explores tangible ways to improve your best practices.

Who should attend?
Professionals involved in benefit-risk strategy from various departments, e.g. pharmacovigilance, regulatory, clinical, drug safety, medical affairs, or medical writing.

Price
Industry Member: EUR 1430,
Industry Non-member: EUR 1585,
Government/Charitable/Non-profit/Academia (Full-Time) Member: EUR 715,
Government/Charitable/Non-profit/Academia (Full-Time) Non-member: USD 870

Speakers: Martin Huber PRAC Member Federal Institute for Drugs and Medical Devices (BfArM) Germany, Steve Mayall PhD Principal Consultant Pope Woodhead and Associates Ltd United Kingdom, Jan Petracek MD MSc CEO PrimeVigilance and PharmInvent Czech Republic, Steffen Thirstrup MD PhD Director NDA Advisory Services Ltd United Kingdom